MA55593A - Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 - Google Patents
Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1Info
- Publication number
- MA55593A MA55593A MA055593A MA55593A MA55593A MA 55593 A MA55593 A MA 55593A MA 055593 A MA055593 A MA 055593A MA 55593 A MA55593 A MA 55593A MA 55593 A MA55593 A MA 55593A
- Authority
- MA
- Morocco
- Prior art keywords
- containing derivatives
- cycles containing
- derivatives serving
- malt1 inhibitors
- pyridine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832608P | 2019-04-11 | 2019-04-11 | |
| EP19178959 | 2019-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55593A true MA55593A (fr) | 2022-02-16 |
Family
ID=70224393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055593A MA55593A (fr) | 2019-04-11 | 2020-04-10 | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12404260B2 (fr) |
| EP (1) | EP3953345B1 (fr) |
| JP (1) | JP7554768B2 (fr) |
| KR (1) | KR20210151880A (fr) |
| CN (1) | CN113677674B (fr) |
| AU (1) | AU2020272156A1 (fr) |
| BR (1) | BR112021019799A2 (fr) |
| ES (1) | ES2949871T3 (fr) |
| MA (1) | MA55593A (fr) |
| MX (1) | MX2021012417A (fr) |
| WO (1) | WO2020208222A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| JP2023549835A (ja) * | 2020-11-12 | 2023-11-29 | モノプテロス セラピューティクス，インコーポレーテッド | がんを治療する材料及び方法 |
| AU2022425324A1 (en) | 2021-12-30 | 2024-05-30 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Tricyclic derivative inhibitor, preparation method therefor, and application thereof |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| GB9925127D0 (en) | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
| ES2338539T3 (es) | 2001-11-01 | 2010-05-10 | Icagen, Inc. | Pirazolamidas para uso en el tratamiento del dolor. |
| AU2004235755A1 (en) | 2003-04-30 | 2004-11-18 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 109P1D4 useful in treatment and detection of cancer |
| ATE482200T1 (de) | 2003-05-01 | 2010-10-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen |
| EP1847531A4 (fr) | 2005-02-09 | 2009-04-22 | Takeda Pharmaceutical | Derive de pyrazole |
| ES2336625T3 (es) | 2006-03-22 | 2010-04-14 | Vertex Pharmaceuticals Incorporated | Inhibidores de la proteina quinasa c-met para el tratamiento de trastornos proliferativos. |
| AU2007273057A1 (en) | 2006-07-12 | 2008-01-17 | Merck Sharp & Dohme Corp. | Substituted pyrazoles as ghrelin receptor antagonists |
| WO2008092292A1 (fr) | 2007-01-17 | 2008-08-07 | The Hong Kong University Of Science And Technology | Composés d'isoquinolone servant d'agonistes sélectifs par rapport à des sous-types pour les récepteurs de la mélatonine mt1 et mt2 |
| JP2010520864A (ja) | 2007-03-09 | 2010-06-17 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | ヒドロキシステロイドデヒドロゲナーゼインヒビターとしてのインドール−及びベンズイミダゾールアミド類 |
| WO2009065897A2 (fr) | 2007-11-21 | 2009-05-28 | Vib Vzw | Inhibiteurs de l'activité protéolytiques de malt1 et leurs utilisations |
| AU2009253812A1 (en) * | 2008-06-04 | 2009-12-10 | Ambrilia Biopharma Inc. | HIV integrase inhibitors from pyridoxine |
| UA103633C2 (ru) | 2008-09-24 | 2013-11-11 | Басф Се | Пиразольные соединения для борьбы с бесхребетными вредителями |
| WO2010039039A1 (fr) | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Formulations orales de dérivés de gemcitabine |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US8252821B2 (en) | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
| WO2011036885A1 (fr) | 2009-09-25 | 2011-03-31 | 武田薬品工業株式会社 | Composé hétérocyclique |
| US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| NZ702485A (en) | 2010-06-03 | 2016-04-29 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| CN102947270B (zh) | 2010-06-22 | 2015-04-08 | 巴斯夫欧洲公司 | 制备4-羟基吡啶的方法 |
| EP2590968A1 (fr) | 2010-07-06 | 2013-05-15 | Novartis AG | Composés éthers cycliques utiles comme inhibiteurs de kinase |
| TW201236685A (en) | 2010-11-11 | 2012-09-16 | Daiichi Sankyo Co Ltd | New pyrazole amide derivatives |
| CN104507933B (zh) | 2012-05-31 | 2017-10-31 | 霍夫曼-拉罗奇有限公司 | 氨基喹唑啉和吡啶并嘧啶衍生物 |
| WO2014033447A2 (fr) * | 2012-08-29 | 2014-03-06 | Respivert Limited | Inhibiteurs de kinase |
| MX2015005744A (es) | 2012-11-09 | 2016-02-10 | Univ Cornell | Inhibidores de malti de molecula pequeña. |
| WO2014086478A1 (fr) | 2012-12-03 | 2014-06-12 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Inhibiteurs de la protéase malt1 |
| HK1216300A1 (zh) | 2013-01-10 | 2016-11-04 | Grünenthal GmbH | 作为crac通道抑制剂的基於吡唑基的甲醯胺i |
| AP2016009487A0 (en) | 2014-05-28 | 2016-10-31 | Novartis Ag | Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors |
| WO2015192081A1 (fr) | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarqueur permettant de prédire la réponse d'une llc à un traitement avec un inhibiteur de la btk |
| WO2016005994A2 (fr) | 2014-07-06 | 2016-01-14 | Gattefosse India Pvt. Ltd. | Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires |
| WO2016022853A1 (fr) | 2014-08-08 | 2016-02-11 | Pharmacyclics Llc | Combinaisons d'inhibiteurs de tyrosine kinase de bruton et leurs utilisations |
| US9879021B2 (en) * | 2014-09-10 | 2018-01-30 | Glaxosmithkline Intellectual Property Development Limited | Compounds as rearranged during transfection (RET) inhibitors |
| HK1244427A1 (zh) | 2014-12-06 | 2018-08-10 | Intra-Cellular Therapies, Inc. | 有机化合物 |
| US10835524B2 (en) | 2015-06-24 | 2020-11-17 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of pancreatic cancer and uses thereof |
| US10065963B2 (en) * | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| WO2017081641A1 (fr) * | 2015-11-13 | 2017-05-18 | Novartis Ag | Nouveaux dérivés de pyrazolo-pyrimidine |
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| WO2017151786A1 (fr) | 2016-03-01 | 2017-09-08 | University Of Maryland, Baltimore | Inhibiteurs de la voie de signalisation wnt pour le traitement de maladies |
| US20190275012A9 (en) | 2016-07-29 | 2019-09-12 | Lupin Limited | Substituted thiazolo-pyridine compounds as malt1 inhibitors |
| WO2018103060A1 (fr) | 2016-12-09 | 2018-06-14 | Janssen Pharmaceutica Nv | Inhibiteurs de tyrosine kinase de bruton et leurs procédés d'utilisation |
| FI3478719T6 (fi) | 2016-12-21 | 2025-01-20 | Mereo Biopharma 3 Limited | Anti-sklerostiini-vasta-aineiden käyttö synnynnäisen luutumisvajauden hoitamisessa |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| AU2017383236B2 (en) | 2016-12-21 | 2022-02-10 | Acerta Pharma B.V. | Imidazopyrazine inhibitors of Bruton's tyrosine kinase |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| US20200009135A1 (en) | 2017-02-01 | 2020-01-09 | Medivir Ab | Therapeutic applications of malt1 inhibitors |
| US11248007B2 (en) * | 2017-03-08 | 2022-02-15 | Cornell University | Inhibitors of MALT1 and uses thereof |
| WO2018226150A1 (fr) | 2017-06-05 | 2018-12-13 | Medivir Aktiebolag | Pyrazolopyrimidine utilisés en tant qu'inhibiteurs de malt-1 |
| BR112020013285A2 (pt) | 2017-12-28 | 2020-12-01 | The General Hospital Corporation | direcionamento do complexo de sinalossoma cbm que induz células t reguladoras a atingirem o microambiente tumoral |
| EP3756268A1 (fr) | 2018-02-23 | 2020-12-30 | Industrieanlagen-Betriebsgesellschaft mbH | Dispositif de génération d'un champ magnétique, notamment pour un système de charge inductif, et dispositif primaire d'un système de charge inductif pour la charge dynamique de véhicules |
| MX2020013699A (es) | 2018-06-18 | 2021-05-12 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| US11040031B2 (en) * | 2018-06-18 | 2021-06-22 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| KR20210132099A (ko) | 2019-02-22 | 2021-11-03 | 얀센 파마슈티카 엔.브이. | 약제학적 제형 |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
| EP3953345B1 (fr) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Dérivés de pyridines comme inhibiteurs de malt1 |
| EP4061966A1 (fr) | 2019-11-22 | 2022-09-28 | Janssen Pharmaceutica NV | Essai d'expression génique régulée par nf-kb pour évaluer l'efficacité d'inhibiteurs de malt1 |
| WO2021099609A1 (fr) | 2019-11-22 | 2021-05-27 | Janssen Pharmaceutica Nv | Procédés d'évaluation de l'efficacité d'inhibiteurs de malt1 à l'aide d'un dosage de translocation nf-kb |
| WO2021138298A1 (fr) | 2019-12-30 | 2021-07-08 | Rheos Medicines, Inc. | Modulateurs de malt1 et leurs utilisations |
| EP4199911A1 (fr) | 2020-08-21 | 2023-06-28 | JANSSEN Pharmaceutica NV | Formulations pharmaceutiques comprenant un inhibiteur de malt1 et un mélange de polyéthylèneglycol et d'un acide gras |
| US20220056012A1 (en) | 2020-08-21 | 2022-02-24 | Janssen Pharmaceutica Nv | Amorphous form of a malt1 inhibitor and formulations thereof |
| US20240299376A1 (en) | 2021-03-03 | 2024-09-12 | Janssen Pharmaceutica Nv | Method of treating a condition using a therapeutically effective dose of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide |
| AU2022231352A1 (en) | 2021-03-03 | 2023-10-19 | Janssen Pharmaceutica Nv | Combination therapy using a malt1 inhibitor and a btk inhibitor |
-
2020
- 2020-04-10 EP EP20717667.8A patent/EP3953345B1/fr active Active
- 2020-04-10 BR BR112021019799A patent/BR112021019799A2/pt not_active Application Discontinuation
- 2020-04-10 KR KR1020217036345A patent/KR20210151880A/ko not_active Withdrawn
- 2020-04-10 MX MX2021012417A patent/MX2021012417A/es unknown
- 2020-04-10 WO PCT/EP2020/060307 patent/WO2020208222A1/fr not_active Ceased
- 2020-04-10 AU AU2020272156A patent/AU2020272156A1/en not_active Abandoned
- 2020-04-10 ES ES20717667T patent/ES2949871T3/es active Active
- 2020-04-10 MA MA055593A patent/MA55593A/fr unknown
- 2020-04-10 CN CN202080028070.1A patent/CN113677674B/zh active Active
- 2020-04-10 US US17/602,885 patent/US12404260B2/en active Active
- 2020-04-10 JP JP2021559711A patent/JP7554768B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020272156A1 (en) | 2021-10-14 |
| JP7554768B2 (ja) | 2024-09-20 |
| KR20210151880A (ko) | 2021-12-14 |
| ES2949871T3 (es) | 2023-10-03 |
| US20220162187A1 (en) | 2022-05-26 |
| CN113677674B (zh) | 2024-08-23 |
| CN113677674A (zh) | 2021-11-19 |
| US12404260B2 (en) | 2025-09-02 |
| BR112021019799A2 (pt) | 2021-12-07 |
| EP3953345A1 (fr) | 2022-02-16 |
| CA3131856A1 (fr) | 2020-10-15 |
| WO2020208222A1 (fr) | 2020-10-15 |
| MX2021012417A (es) | 2021-11-12 |
| EP3953345B1 (fr) | 2023-04-05 |
| JP2022528919A (ja) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55593A (fr) | Cycles pyridine contenant des dérivés servant d'inhibiteurs de malt1 | |
| MA54755A (fr) | Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4 | |
| PH12020550786A1 (en) | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
| AR106237A2 (es) | Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables | |
| MA56021A (fr) | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA49013A (fr) | Nouveaux dérivés hétérocycliques utiles en tant qu'inhibiteurs de shp2 | |
| GEAP202115066A (en) | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS | |
| SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
| MX2013007104A (es) | Derivados de biciclo[3,2,1]octilamida y sus usos. | |
| CR10359A (es) | Derivados de dihidropirazolopirimidinona | |
| GEAP202015169A (en) | Tyrosine amide derivatives as rho-kinase inhibitors | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| MA41901A (fr) | Compositions contenant de l'ibrutinib | |
| UY31940A (es) | Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones | |
| EP3733673A4 (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| EP3941525A4 (fr) | Dérivés de benzodiazépine en tant qu'inhibiteurs de rsv | |
| EP3733671A4 (fr) | Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase | |
| PE20180412A1 (es) | Compuestos inhibidores de la senalizacion de la via de notch | |
| EP3449001A4 (fr) | Inhibition de l'arnmi mir-22 par apt-110 | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| CY1116168T1 (el) | Συγκρυσταλλοι και αλατα αναστολεων toy ccr3 | |
| EP3946288A4 (fr) | Dérivés de 5-cyclopropyl-1h-pyrazol-3-yl-amine substitués utilisés en tant qu'inhibiteurs sélectifs de cdk12/13 | |
| MA50439A (fr) | Nouveaux dérivés de pyrazolo-pyrrolo-pyrimidine-dione utilisés en tant qu'inhibiteurs de p2x3 | |
| MA53643A (fr) | Dioxocyclobuténylamino-3-hydroxy-picolinamides n-substitués utiles en tant qu'inhibiteurs de ccr6 |